Pathstone Family Office’s Novartis NVS Stock Holding History

Pathstone Family Office’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$2.67M	Buy	26,255 +7,594	+41%	+$771K	0.02%	408
2023 Q2	$1.87M	Sell	18,661 -861	-4%	-$86.1K	0.03%	330
2023 Q1	$1.73M	Sell	19,522 -31,926	-62%	-$2.79M	0.03%	312
2022 Q4	$4.14M	Buy	51,448 +4,809	+10%	+$405K	0.04%	313
2022 Q3	$3.55M	Buy	46,639 +29,924	+179%	+$2.48M	0.03%	295
2022 Q2	$1.41M	Buy	16,715 +3,823	+30%	+$335K	0.03%	269
2022 Q1	$1.14M	Buy	12,892 +975	+8%	+$84.4K	0.03%	298
2021 Q4	$1.04M	Sell	11,917 -206	-2%	-$17.1K	0.03%	328
2021 Q3	$992K	Buy	12,123 +1,791	+17%	+$161K	0.03%	301
2021 Q2	$943K	Buy	10,332 +3,241	+46%	+$289K	0.03%	285
2021 Q1	$606K	Buy	7,091 +6,323	+823%	+$567K	0.02%	307
2020 Q4	$73K	Buy	768 +13	+2%	+$1.14K	﹤0.01%	447
2020 Q3	$66K	Hold	755	–	–	0.01%	326
2020 Q2	$66K	Hold	755	–	–	0.01%	276
2020 Q1	$62K	Sell	755 -296	-28%	-$26.4K	0.01%	269
2019 Q4	$996K	Buy	1,051 +296	+39%	+$26.6K	0.01%	214
2019 Q3	$66K	Hold	755	–	–	0.01%	231
2019 Q2	$69K	Sell	755 -323	-30%	-$27.3K	0.01%	284
2019 Q1	$93K	Buy	1,078 +235	+28%	+$18.9K	0.01%	231
2018 Q4	$65K	Buy	+843	New	+$65.6K	0.02%	161
2018 Q2	–	Sell	-121	Closed	-$9K	–	273
2018 Q1	$9K	Buy	+121	New	+$9.21K	0.01%	235
2017 Q3	–	Sell	-781	Closed	-$59K	–	291
2017 Q2	$59K	Buy	781 +569	+268%	+$40.3K	0.02%	182
2017 Q1	$14K	Buy	+212	New	+$14.1K	0.01%	257
2013 Q4	–	Sell	-73	Closed	-$5K	–	299
2013 Q3	$5K	Sell	73 -43	-37%	-$2.85K	0.02%	220
2013 Q2	$8K	Buy	+116	New	+$7.55K	0.01%	255

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pathstone Family Office's NVS Position: Q3 2023 in Review

Pathstone Family Office increased its Novartis (NVS) stake by 41% in Q3 2023, buying an estimated $771K and bringing the position to 26,255 shares worth $2.67M. The position accounts for 0.02% of the portfolio, ranked #408.

Pathstone Family Office first reported a position in NVS in Q2 2013 and has held it in 25 quarters since. The position peaked at $4.14M in Q4 2022. 1,223 funds tracked by Wall St. Rank hold NVS as of Q3 2023.

Pathstone Family Office held 26,255 shares of Novartis worth $2.67M as of Q3 2023.
Pathstone Family Office bought 7,594 Novartis shares in Q3 2023, an estimated $771K.
Novartis made up 0.02% of Pathstone Family Office's portfolio in Q3 2023, its #408 holding.
Pathstone Family Office first reported a position in Novartis in Q2 2013 and has held it in 25 quarters since.
Pathstone Family Office's Novartis position peaked at $4.14M in Q4 2022.
1,223 funds tracked by Wall St. Rank held Novartis as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.